Advertisement

Topics

Companies Related to "Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration" [Most Relevant Company Matches] RSS

02:09 EDT 20th June 2018 | BioPortfolio

Here are the most relevant search results for "Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration" found in our extensive corporate database of over 50,000 company records.

Showing "Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration" Companies 1–25 of 5,800+

Extremely Relevant

Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of “universal” vaccines capable of protecting against multiple – including newly emergent, unknown – stra...


Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. The company’s SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. When delivered with Inovio’s proprietary electroporation ...

Relevant

Life Science Pharmaceuticals

Life Science Pharmaceuticals, Inc. (LSP) is a biopharmaceutical company dedicated to developing drugs for cancer and other serious diseases. LSP entered into a strategic collaboration to develop mAb 806 and other cancer therapeutics developed by Lloyd J. Old and the dedicated scientists at the Ludwig Institute for Cancer Research in 2006. An LSP mon...


Inovio Biomedical

Inovio Biomedical Corporation (AMEX: INO) is a leader in cancer and other medical therapies using electroporation-enabled delivery of useful biopharmaceuticalsInovio Biomedical Corporation (AMEX: INO) is a late stage biomedical company developing novel therapies enabled by electroporation, with a focus on addressing critical unmet treatment needs in oncology. Clinical results validate its local ca...

Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company has fo...

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines for the treatment of cancer and infectious diseases. The company's pharmacologically regulated DeCIDe(TM) vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific TH1 immune response. Lead product BPX-101, an autologous DeCIDe(TM) vaccine, is in clinical development...

Swiss Vaccine Research Institute

The SVRI is a partnership of five research institutes in Switzerland. The SVRI was created in 2007 in Lausanne and is supported by the Swiss Secretariat of Education and Research. Its primary objective is to develop effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer. SVRI plays an instrument...

Biotech Synergy

Biotech Synergy has secured in San Diego the necessary competences to bring this promising multi epitope cancer vaccine to latest stage development. Contrary to Dendreon individualized vaccine, EP-2101 is made of 10 peptides and is an off the shelf readily available vaccine for the HLA-A2 population, which represents 45% of the global NSCLC patients (100,0...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, oncology and virology. Progeni...

Biomira

Biomira Inc. (TSE: BRA; Nasdaq: BIOM) is a product focused biotechnology company applying its proprietary immunotherapy and organic chemistry technologies for the development of cancer therapeutics. The Company's lead product, THERATOPE® vaccine, is currently being tested in a Phase III clinical trial for metastatic breast cancer. The Company's commitment to the development of products for the ...

Prolx Pharmaceuticals LP

PROLX Pharmaceuticals is a privately held biopharmaceutical company dedicated to the discovery of novel target-based therapeutics for the treatment of cancer. PROLX was established to rapidly move novel, proprietary, small molecule pharmaceuticals through pre-clinical development and into clinical trials. Seminal research being conducted by PROLX in collaboration with several leading universitie...

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals welcomes you to our website to learn about our important novel technology for the treatment of cancer. As part of a worldwide race for a cure for cancer, Actinium Pharmaceuticals Inc. is developing a safe and highly effective therapy for cancer and other life threatening cellular diseases through Alpha Particle Immunotherapy (APIT). APIT is a groundbreaking technology in t...

Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our p...

AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. AVAX’s AC Vaccine platform is a therapeutic cancer vaccine. In addition, the Company performs contract-manufacturing services for...

Aphton Corporation

Aphton Corporation is a biopharmaceutical company developing products using its innovative vaccine-like technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and non-cancer diseases; and the prevention of pregnancy. Aphton has strategic alliances with Pasteur Merieux Connaught (Rhone-Poulenc Group), SmithKline Beecham, Schering-Plo...

Agios Pharmaceuticals, Inc.

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic, in addition to an active research and discovery pipeline across ...

Avantogen Oncology

Avantogen Limited is a drug development Company whose current activities are focused on its three product candidates, namely, RP101 (a potential therapy for pancreatic cancer), GPI-0100 (vaccine adjuvants) and Pentrys™ (cancer vaccine). The Company is currently overseeing Phase II human testing of RP101 in Germany, Phase I human testing of GPI-0100 in the U.S and Phase II human testing of the P...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

GenVec

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates use a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. TNFerade™ represents a novel approach to treating cancer in combination with rad...

Cancer Cytogenomics Microarray Consortium (CCMC)

The Cancer Cytogenomics Microarray Consortium (CCMC) was formed in August 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists who are interested in applying microarray technologies to cancer diagnosis and cancer research. The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. Our goals are to...

Nuvera Biosciences

Nuvera Biosciences is a venture launched in collaboration with The University of Texas M. D. Anderson Cancer Center (MDACC). The Company is focused on developing novel molecular diagnostics that make a significant impact on cancer care by improving detection techniques and treatment selection in cancer.MDACC has world-renowned capabilities in cancer molecular research, cancer care, and drug trials...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the N...

Vertex Pharmaceuticals Inc.

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. Founded in 1989, Vertex today employs more than 2,000 people at sites around the world.  In addition to our headquarters in Massachusetts, Vertex has research and development sites and other offices in San Diego, CA; Abingd...


More From BioPortfolio on "Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks